1. Home
  2. BLZE vs ALXO Comparison

BLZE vs ALXO Comparison

Compare BLZE & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Backblaze Inc.

BLZE

Backblaze Inc.

N/A

Current Price

$18.71

Market Cap

218.8M

Sector

Technology

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.93

Market Cap

205.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BLZE
ALXO
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
218.8M
205.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BLZE
ALXO
Price
$18.71
$1.93
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$7.60
$3.50
AVG Volume (30 Days)
2.8M
975.4K
Earning Date
05-04-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
58.56
26.36
EPS
N/A
N/A
Revenue
$145,835,000.00
N/A
Revenue This Year
$10.16
N/A
Revenue Next Year
$10.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.27
N/A
52 Week Low
$3.26
$0.62
52 Week High
$23.99
$2.66

Technical Indicators

Market Signals
Indicator
BLZE
ALXO
Relative Strength Index (RSI) 65.59 48.68
Support Level $3.93 $1.93
Resistance Level $23.99 $2.27
Average True Range (ATR) 1.58 0.13
MACD 0.49 -0.00
Stochastic Oscillator 59.80 36.37

Price Performance

Historical Comparison
BLZE
ALXO

About BLZE Backblaze Inc.

Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: